Translated Titles

The Study of the Cancer Patients’ Constitution Changes Before and After Receiving Radiotherapy





Key Words

體質 ; 放射線治療 ; constitution ; radiotherapy



Volume or Term/Year and Month of Publication


Academic Degree Category




Content Language


Chinese Abstract

癌症的發生率及死亡率居高不下,現代醫學使用放射療法作為其中一種主要的治療方式。然而,放射療法在治療過程中,難免對於正常細胞帶來損傷,產生副作用。現代醫學的評估,副作用的產生與放療的照射方式、劑量、及病人體質有很大的關係,而體質一直是現代醫學難以突破的課題,所以,本研究嘗試從中醫理論的角度評估患者體質與副作用的相關性。 本研究自97年3月1日起至98年4月11日止,於三軍總醫院放射腫瘤科門診進行取樣施測,完成第一、二階段評估的總共有46位病患。中醫體質的評估,採用BCQ中醫體質量表;放射線療法副作用的評估,採用美國放療組織(RTOG)所研發出的分級量表,並進行T檢定、淨相關檢定等統計分析。 本研究之結果顯示:病患接受放射線治療後的各類型體質(陰血虛、陽氣虛、痰濕瘀滯)分數皆有顯著上升(加重);副作用嚴重度與總照射劑量無顯著相關,反而與治療前的痰瘀體質和治療過程中陰血虛的變化量呈顯著正相關。這意謂著:體質會受放射線療法影響而轉變,更與副作用之嚴重度息息相關,藉由體質分析,可提供分期治療之策略,彰顯中醫體質調整之重要性。

English Abstract

The morbidity and mortality rate of cancer are still high. Radiotherapy is the major method for cancer treatment in modern medicine. However, the cell damage caused by radiotherapy will result in certain degree of adverse effects. The manifestations of the adverse effects are in relation with the radiation methods, dosage and the constitution of the patients. Thus, this study aimed to explore the constitution changes of the cancer patients before and after receiving radiotherapy. This study was conducted from March 01, 2008 to November 11, 2009. Forty-six patients with different cancer diagnosis were observed in the outpatient department of Radiation Oncology in Tri-service General Hospital. The patients’ constitution was evaluated by body constitution questionnaire (BCQ) and their adverse effects were assessed by grading table made by RTOG. The result revealed the scores of Yin-Xu, Yang-Xu and Stasis constitution all elevated after radiotherapy. There was no significant correlation between the severity of adverse effects and total dose of radiation; but the severity of adverse effects was significantly correlated with the score of Stasis constitution and the change of Yin-Xu constitution score. Our results implies that the patient’ constitution will change after radiotherapy and has correlation with the severity of adverse effects. Therefore, the patients’ adverse effects may be prevented by adjusting their constitution.

Topic Category 醫藥衛生 > 中醫藥學
中醫學院 > 中醫學系碩士班
  1. 1.行政院衛生署. 歷年死因統計. 台灣,2009.
  2. 2.行政院衛生署. 癌症登記報告. 台灣,2008.
  3. 7.J. Robert Andrews. Benefit, risk, and optimization by roc analysis in cancer radiotherapy. International Journal of Radiation Oncology Biology Physics. 1985;11(8): 1557-1562.
  4. 10.Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). International Journal of Radiation Oncology Biology Physics. 1995;31:1341-1346.
  5. 11.Doherty DG, Burnett WT. Jr. Protective effect of S, beta-aminoethylisothiuronium-Br-HBr and related compounds against x-radiation death in mice. Proceedings of the society for experimental Biology and Medicine. 1955;89(2):312-314.
  6. 12.Lee E J, Gerhold M, Palmer M W, Christen R D . P53 protein regulates the effects of amifostine on apoptosis, cell cycle progression and cytoprotection. British Journal of Cancer, 2003;88(5):754-759.
  7. 13.André Deeke Sasse, Luciana Gontijo de Oliveira Clark, Emma Chen Sasse, Otávio Augusto Camara Clark. Amifostine reduces side effects and improves complete response rate during radiotherapy: Results of a meta-analysis Original Research Article. International Journal of Radiation Oncology Biology Physics. 2006;64(3):784-791.
  8. 14.Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). European Journal Cancer. 1996;32(4):5–16.
  9. 15.Buschini A, Alessandrini C, Martine A, Pasini L, Rizzoli V, Carlo-Stella C, Poli P, Rossi C. Bleomycin genotoxicity and amifostine(WR-2721) cell protection in normal leukocytes vs. K562 tumoral cells. Biochem Pharmacol. 2002;(63):967-975.
  10. 16.Wagner W, Prott F-J, Schonekas KG. Amifostine: a radioprotector in locally advanced head and neck tumors. Oncology Reports. 1998;5:1255-1257.
  11. 17.Chien-An Chen, Chen-His Hsieh, Yuen-Liang Lai, Moon-Sing Lee, Yuen-Jen Chen, Shih-Kai Hung. Side Efects of Amifostine with Concurrent Chemoradiation Therapy for Head and Neck Cancer. Therapeutic Radiology Oncology. 2006; 13(2):127-133.
  12. 18.陳舜鼎, 張國華, 陳裕仁, 鍾昌宏, 吳孟浩, 蘇文浩, 陳虹汶, 賴允亮. 雙盲對照實驗評估口服pilocarpine對放射線治療引起頭頸部癌症病患口乾症於馬偕醫院之使用主觀效果及安全性報告. 放射治療與腫瘤學. 2003;10(1):11-18.
  13. 19.Pauwels B, Korst A E, dePooter C M, Lambrechts HA, Pattyn GG, Lardon F, Vermorken JB. The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro. European Journal of Cancer. 2003;39(6): 838-846.
  14. 29.Rothwell P. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365(9454):176-186.
  15. 30.Rothwell P, Methta Z, Howard S, Gutnikov S, Warlow C. From subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet. 2005;365(9455):256-265.
  16. 31.Summerskill W. Evidence-based practice and the individual. Lancet. 2005;365 (9453):13-14.
  17. 32.Chae H, Lyoo IK, Lee SJ, Cho S, Bae H, Hong M, Shin M. An alternative way toindividualized medicine: psychological and physical traits of sasang typology. J Altern Complement Med. 2003;9(4):519-528.
  18. 33.Chen RQ, Cao KJ, Lam TH, Wong CM. Symptom characteristics of Kidney-Yin deficiency and Kidney-Yang deficiency in Hong Kong Chinese midlife women. J Altern Complement Med. 2008;14(5):457-460.
  19. 34.Lee S, Park J, Lee H, Kim K. Development and validation of Yin-deficiency questionnaire. Am J Chin Med. 2007;35(1):11-20.
  20. 37.彭台珠, 李明憲. 女性陰性體質量表之發展與建立. 醫護科技學刊. 2002;3(4): 315-329.
  21. 38.陳敬修, 邱創乾, 宋慶龍, 張永賢. 利用心率變異數評估中醫陰陽體質之研究. Journal of Medical and Biological Engineering. 2002;22(S):s91-s98.
  22. 42.陳麗麗. 中醫陽氣虛體質量表之發展. 中國醫藥大學中國醫學研究所. 2009;pp. 4.
  23. 54.Langevin HM, Badger GJ, Povolny BK, Davis RT, Johnston AC, Sherman KJ, Kahn JR, Kaptchuk TJ. Yin scores and Yang scores: A new method for quantitative diagnostic evaluation in traditional Chinese medicine research. J Altern Complement Med. 2004;10(2):389-395.
  24. 58.Yi-Chang Su, Li-Li Chen, Jun-Dai Lin, Jui-Shan Lin, Yi-chia Huang, Jim-Shoung Lai. BCQ+ A Body Constitution Questionnaire to Assess Yang-Xu Part I: Establishment of a First Final Version through a Delphi Process. Forschende Komplementärmedizin. 2008;15(6):327-334.
  25. 59.Li-Li Chen, Jui-Shan Lin, Jun-Dai Lin, Chih-Hung Chang, Hsien-Wen Kuo, Wen-Miin Liang, Yi-Chang Su. BCQ+ A Body Constitution Questionnaire to Assess Yang-Xu Part II: Evaluation of Reliability and Validity. Forschende Komplementärmedizin. 2009;16(1):20-27.
  26. 3.吳錦榕, 林光大. 放射線治療癌症之臨床應用. 國防醫學雜誌. 1988;7(4):335-340.
  27. 4.TCOG放射療法委員會. 放射治療共識. 國家衛生研究院 2003; pp. 13.
  28. 5.陳俊杰,祝希媛. 放射性損傷的中醫證候學研究. 北京中醫藥大學學報. 1999;22(5):43-44.
  29. 6.王瑞平. 從清熱養陰論治惡性腫瘤放療所致放射性損傷. 江蘇中醫藥. 2006;27(12):24-25.
  30. 8.TCOG放射療法委員會. 放射治療共識. 國家衛生研究院. 2003; pp. 13.
  31. 9.腫瘤放療併發症防治. 人民軍醫出版社. 2008;pp. 17-18.
  32. 20.譚常青, 賴州. 放射保護劑及放射性皮膚損傷防治的研究進展. 食品與藥品. 2006;8(7):25-28.
  33. 21.王瑞平. 從清熱養陰論治惡性腫瘤放療所致放射性損傷. 江蘇中醫藥. 2006;27(12):24-25.
  34. 22.陳俊杰, 祝希媛. 放射性損傷的中醫證候學研究. 北京中醫藥大學學報. 1999;22(5)43-44.
  35. 23.孫華麗. 扶正增效方對惡性腫瘤放射增效作用的臨床和實驗研究. 中醫雜誌. 1990;31(6)25-29.
  36. 24.陳建明. 癌症患者舌質動態變化的臨床意義. 中醫雜誌. 1999;40(10):636-637.
  37. 25.孫紅友. 腫瘤患者手術、放化療前後中醫證候研究近況. 新疆中醫藥. 2004;22(4):51-54.
  38. 26.腫瘤研究. 知音出版社. 1994;pp. 81-85.
  39. 27.王梅, 張紅軍, 單昉昉, 安永恆, 周仁祥, 于洪升. 青地湯防治鼻咽癌放療反應近期療效觀察. 山東中醫藥大學學報. 1999;23(1)53-54.
  40. 28.鄭承鐸., 鄭立升., 楊曉云., 張萍. 福州人飲食性味涼熱和溫度高低與體質關係研究. 中國中醫基礎醫學雜誌. 2002;8(2):58-61.
  41. 35.朱燕波, 王琦, 折笠秀樹. 中醫體質量表的信度與效度評價. 中國行為醫學科 學. 2007;16(7):651-654.
  42. 36.王琦, 朱燕波, 薛禾生, 李稍. 中醫體質量表的初步編制. 中國臨床康復. 2006;10(3):15-17.
  43. 39.葉福媛, 宋莉君, 孫愛貞. 中醫體質的實驗性研究-寒體和熱體大鼠多元素多因子分析. 廣東微量元素科學. 2000;7(2):16-18.
  44. 40.張永賢. 從自律神經功能探討中醫體質之研究. 行政院衛生署中醫藥年報. 1999;17(2):35-53.
  45. 41.王琦. 9種基本中醫體質類型的分類及其診斷表述依據. 北京中醫藥大學學報. 2005;28(4):1-8.
  46. 43.蘇奕彰. 系統性紅斑狼瘡患者之中醫體質研究. 博士論文, 中國醫藥大學, 1995.
  47. 44.王琦, 朱燕波, 薛禾生, 李稍. 中醫體質量表的初步編制. 中國臨床康復. 2006;10(3):15-17.
  48. 45.馬建中. 中醫診斷學. 台北: 正中書局, 1980.
  49. 46.鄧鐵濤. 中醫證候規範. 廣州: 廣東科技出版, 1990.
  50. 47.柯雪帆. 中醫辨證學. 上海: 上海中醫學院, 1987.
  51. 48.陳國林, 潘其民, 趙玉秋, 陳澤奇, 黎性群, 傅孟如, 歐陽曉光. 中醫肝病證候臨床辯證標準的研究. 中國醫藥學報. 1990;5(1):66-70.
  52. 49.何裕民. 體質結構研究. 中國醫藥學報. 1989:4(6):33-36.
  53. 50.何裕民. 體質研究-現時代中西醫學的最佳交融點. 醫學與哲學. 1996;17(6): 288-291.
  54. 51.冷方南. 中醫證候辯治規範. 北京: 人民衛生出版社, 1989.
  55. 52.匡調元. 論氣象病理與體質病理. 上海中醫藥雜誌. 1981;6:31-35.
  56. 53.張敏, 戴曉勇, 劉瑤, 童蓓麗, 陸慶榮, 施永興, 陳耀玉. 1763例社區人員中醫體質篩查分析. 河南中醫. 2002; 22(4):71-73.
  57. 55.姚實林, 吳芳斌, 許霞, 曹健, 王文銳, 李成國. 1003例中醫體質類型流行病學調查調查分析. 安徽中醫學院學報. 2007;26(1):10-13.
  58. 56.張偉榮, 張慶彝. 略論體質病理學的基因研究. 中國中醫基礎醫學雜誌. 2002;8(2):58-61.
  59. 57.蘇奕彰. 過敏性鼻炎患者中醫體質類型與基因及蛋白質表現之相關性研究. 行政院衛生署中醫藥年報. 2005;23(7):83-116.